CA
NZ
UK
AU
IND
US
Average selling prices rose 6% and sales volumes fell 1%. Prices were higher for polyethylene, PVC resin, caustic soda and epoxy resin. Performance and Essential Materials sales grew 8% to USD 1,894 million on a 9% price gain, with Performance Materials up 16% to …
Product revenue grew 13.9% to USD 108.7 million, while service revenue slipped 2.9% to USD 29.1 million. Window film revenue increased 11.8% and made up 22.4% of the total, and installation revenue, combining labor and product, grew 4.5%.
Total bookings reached USD 323.5 million, up 24.4%. Active CLEAR+ members grew 14.5% to 8.5 million, and total CLEAR members rose 30.7% to 46.7 million. Founder and chief executive Caryn Seidman-Becker said the company is extending its identity platform from airport checkpoints to cybersecurity, …
Growth varied sharply by product group. Hips sales rose 6.0% to USD 536.5 million, or 7.0% in constant currency. The S.E.T. group, which covers sports medicine, biologics, foot and ankle, upper extremities, trauma and related lines, grew 6.8% to USD 578.3 million. Technology and …
Published market data lists one-year EPS growth for ACCO Brands (NYSE:ACCO) at 61.71%, which we could not match to a filing. The company figures we could confirm are adjusted EPS growth of about 33% for the quarter (USD 0.28 against USD 0.21, our arithmetic) …
Key HighlightsAdeia (NASDAQ:ADEA) reported third-quarter 2026Revenueof USD 80.2 million on November 2, 2026, down from USD 87.3 million a year earlier and USD 96.1 million in the second quarter.GAAPNet Incomewas USD 2.3 million, or USD 0.02 per diluted share, against USD 8.8 million, or …
IBSRELA generated USD 96.3 million, up 23%, and now supplies most of the revenue, while XPHOZAH generated USD 29.2 million, up 7%. The company reiterated full-year 2026 IBSRELA revenue guidance of USD 350 million to USD 370 million and XPHOZAH guidance of USD 110 …
Fuel was the main cost pressure. Fuel expense rose to USD 425 million from USD 234 million, and adjusted cost per available seat mile, excluding fuel, was 7.84 cents. For the fourth quarter, the company guides to adjusted EPS of negative USD 0.15 to …
The company said its rolling new drug application for COMP360 in treatment-resistant depression is under review as it is submitted, and it expects to file the final portion within two weeks. No acceptance or action date has been disclosed. It also said a National …
Reserves for expectedCreditlosses were USD 566.2 million, or 18.5% of unpaid principal. Agreements to sell two risk-rated 5 loans for USD 310.7 million of gross proceeds became binding in October, with expected incremental losses of USD 10.4 million, or about USD 0.07 per share, …
Please wait processing your request...